Triple threat: new combo tackles stubborn breast cancer
NCT ID NCT04095689
First seen Jan 23, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tested a mix of chemotherapy (docetaxel), an immunotherapy drug (pembrolizumab), and a gene therapy (IL-12) in 8 women with a tough-to-treat type of breast cancer that had stopped responding to standard treatment. The goal was to see if this combination could shrink or eliminate tumors. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.